Table 5 Cost, utility, and discount rate input.

From: Cost-effectiveness analysis of COPD screening programs in primary care for high-risk patients in China

Parameter

Values

Source/assumption

OWSA

Lower

Upper

Drug costs per month (¥)

 LAMA + LABA

¥642

IQVIA CHPA 2018

¥513

¥770

 LABA + ICS

¥114

IQVIA CHPA 2018

¥91

¥136

 LABA alone

¥124

IQVIA CHPA 2018

¥99

¥149

 LAMA alone

¥253

IQVIA CHPA 2018

¥202

¥303

 LABA + LAMA + ICS

¥366

IQVIA CHPA 2018

¥292

¥439

Cost of COPD maintenance (oxygen inhalation, expectorant, etc) per month (¥)

 Mild COPD

¥23

39

¥18

¥27

 Moderate COPD

¥67

39

¥54

¥81

 Severe/very severe COPD

¥187

39

¥150

¥225

Cost of CB treatment per month (¥)

¥288

IQVIA CHPA 2018

¥100

¥500

 Amoxicillin

¥10

IQVIA CHPA 2018

 Dextromethorphan

¥27

IQVIA CHPA 2018

 Ambroxol hydrochloride

¥224

IQVIA CHPA 2018

 Aminophylline

¥20

IQVIA CHPA 2018

 Ipratropium bromide

¥7

IQVIA CHPA 2018

AE costs (¥)

 Exacerbation treated in inpatient

 Mild COPD

¥8,639

39

¥6,911

¥10,366

 Moderate COPD

¥17,277

39

¥13,822

¥20,732

 Severe/very severe COPD

¥25,915

39

¥20,732

¥31,099

 Exacerbation treated in outpatient

¥395

39

¥316

¥474

 Cost of pneumonia

¥32,394

39

¥25,916

¥38,873

Screening and diagnosis costs (¥)

 Cost of portable spirometer screening

¥34

Supplementary Table 9

¥27

¥41

 Cost of questionnaire screening

¥8

Supplementary Table 9

¥6

¥9

 Cost of additional tests to confirm COPD

¥220

Supplementary Table 8

¥176

¥264

Utility

 Mild COPD

0.81

0.65

0.97

 Moderate COPD

0.72

20

0.58

0.86

 Severe/very severe COPD

0.67

20

0.54

0.80

 Correction for exacerbation in outpatient

0.85

36

0.68

0.99

 Correction for exacerbation in inpatient

0.50

36

0.40

0.60

 Correction for serious pneumonia

0.50

36

0.40

0.60

Discount rate

 Effect

3.5%

42

0.00

5.00

 Costs

3.5%

42

0.00

5.00

  1. Exchange rate in 2018 was 1 Chinese Yuan = 0.1511 US Dollar.
  2. KOL key opinion leader, CB chronic bronchitis, CHPA Chinese Hospital Pharmaceutical Audit database, SABA short acting beta agonists, SAMA short acting muscarinic antagonists, LAMA long acting muscarinic antagonists, LABA long acting beta agonists, ICS inhaled corticosteroids.